Related Experiment Video
Updated: Jul 1, 2026
14:34
A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
Published on: April 3, 2026
PLK1: A Promising Therapeutic Target for Prostate Cancer Treatment
Jia Peng1, Mansoureh Nouri1, Hamed Maasoumyhaghighi1
1Department of Toxicology and Cancer Biology, University of Kentucky, Lexington, Kentucky 40536, USA.
Serican Journal of Medicine
|June 30, 2026
Summary
Polo-like kinase 1 (PLK1) drives castration-resistant prostate cancer (CRPC) progression and resistance to therapies. Inhibiting PLK1, potentially with paclitaxel, offers a promising strategy to improve CRPC treatment outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Prostate cancer is a leading cause of cancer mortality in men.
- Androgen deprivation therapy (ADT) is standard for advanced prostate cancer, but resistance leads to lethal castration-resistant prostate cancer (CRPC).
- Next-generation androgen receptor signaling inhibitors (ARSIs) are effective but face resistance challenges.
Purpose of the Study:
- To examine the role of Polo-like kinase 1 (PLK1) in CRPC progression and treatment resistance.
- To explore PLK1's mechanistic involvement in pathways promoting tumor growth and therapy resistance.
- To identify potential combination therapies involving PLK1 inhibition for improved CRPC treatment.
Main Methods:
- Review of recent studies on PLK1's function in prostate cancer.
- Analysis of PLK1's links to oxidative stress, lipid metabolism, and androgen receptor signaling.
- Investigation of PLK1's role in DNA repair, chromosomal stability, and resistance to targeted therapies.
Main Results:
- PLK1 is identified as a key driver of CRPC progression and resistance to ARSIs.
- PLK1 activation is associated with pathways promoting tumor growth and resistance.
- PLK1 influences sensitivity to irradiation therapy and resistance to PARP inhibitors in BRCA-mutant CRPC.
Conclusions:
- PLK1 is a critical therapeutic target in CRPC.
- Combining PLK1 inhibition with therapies like paclitaxel may overcome resistance.
- Targeting PLK1 offers a promising strategy to improve efficacy and outcomes in CRPC treatment.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include: